Michael Angelo Statnick

Title: Michael Angelo Statnick: Innovator in Opioid Receptor Antagonism

Introduction

Michael Angelo Statnick, based in Indianapolis, IN, is an innovative inventor making strides in the pharmaceutical field. With a focus on developing effective treatments for irritable bowel syndrome, Statnick has made significant contributions through his research and inventions.

Latest Patents

Statnick holds a patent for Diaryl ethers as opioid receptor antagonists, specifically the compound 5-(2-Methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof. This invention is aimed at providing a solution for patients suffering from irritable bowel syndrome, showcasing his dedication to addressing medical needs with innovative solutions.

Career Highlights

Statnick has built his career at Eli Lilly and Company, a prominent player in the pharmaceutical industry. His work there emphasizes his commitment to advancing medical treatments through innovative research. His extensive knowledge and experience in the field have positioned him as an influential figure in the development of therapeutic solutions.

Collaborations

In his journey, Statnick collaborates with talented professionals, including his coworker Charles Howard Mitch. Collaborating with experts in the industry enhances the scope of innovation and effectiveness in developing new medicines that hold the potential to improve patients' lives.

Conclusion

Michael Angelo Statnick stands out as a remarkable inventor within the pharmaceutical landscape. His creation of novel compounds to serve as opioid receptor antagonists exemplifies the impact that dedicated inventors can have on healthcare solutions. As he continues his work at Eli Lilly and Company, Statnick is sure to pave the way for future innovations aimed at treating medical conditions effectively.